GRAIL, Inc. $GRAL Stock Holdings Lifted by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL) by 159.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 206,120 shares of the company’s stock after buying an additional 126,576 shares during the period. JPMorgan Chase & Co.’s holdings in GRAIL were worth $12,188,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. NewEdge Advisors LLC increased its holdings in shares of GRAIL by 390.3% in the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after purchasing an additional 1,401 shares during the period. Atlantic Union Bankshares Corp acquired a new position in GRAIL in the 3rd quarter valued at approximately $64,000. Cypress Capital Management LLC WY purchased a new stake in GRAIL in the 2nd quarter worth approximately $72,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock valued at $76,000 after buying an additional 623 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of GRAIL by 278.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,288 shares of the company’s stock valued at $118,000 after buying an additional 1,684 shares during the period.

Insider Activity

In other news, President Joshua J. Ofman sold 17,002 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $50.16, for a total value of $852,820.32. Following the sale, the president directly owned 436,508 shares of the company’s stock, valued at approximately $21,895,241.28. This trade represents a 3.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Ragusa sold 37,504 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $50.17, for a total value of $1,881,575.68. Following the transaction, the chief executive officer directly owned 650,525 shares of the company’s stock, valued at $32,636,839.25. This represents a 5.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 64,079 shares of company stock valued at $3,214,673. 1.85% of the stock is owned by insiders.

Analysts Set New Price Targets

GRAL has been the subject of several recent research reports. Robert W. Baird set a $82.00 price objective on GRAIL in a report on Friday, February 20th. Guggenheim raised their price target on GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. TD Cowen assumed coverage on GRAIL in a report on Thursday, February 19th. They issued a “hold” rating and a $114.00 price objective on the stock. Finally, Canaccord Genuity Group decreased their target price on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $90.17.

GRAIL Stock Down 4.1%

Shares of GRAL stock opened at $51.80 on Friday. GRAIL, Inc. has a 12 month low of $20.44 and a 12 month high of $118.84. The company has a market cap of $2.02 billion, a PE ratio of -4.63 and a beta of 5.18. The business’s 50 day moving average is $89.73 and its two-hundred day moving average is $77.12.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. The business had revenue of $43.60 million during the quarter, compared to the consensus estimate of $43.33 million. As a group, equities analysts expect that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.